RedHill Biopharma Announces Definitive Agreement for $2.5 Million Private Placement From Broadfin Capital LLC
December 31, 2013 09:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Dec. 31, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
Qu Biologics Begins Research with McMaster University to Study New Crohn's Disease Research Model
December 03, 2013 10:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to stimulate the...
Qu Biologics Welcomes Dr. Richard Fedorak and Dr. William Sandborn to Newly Formed IBD Advisory Team for Crohn's Disease Clinical Trial
May 30, 2013 13:43 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 30, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...